CARGO Therapeutics
CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologous CARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.
Domain
cargo-tx.com
Country
United StatesIndustry
BiotechnologyEmployees
101-250
Last Funding
$110.0M
Founded
2020
No technologies detected yet for this company.
Frequently Asked Questions
What technologies does CARGO Therapeutics use?+
We have not yet detected technologies for CARGO Therapeutics.
What industry is CARGO Therapeutics in?+
CARGO Therapeutics operates in the Biotechnology industry.
Where is CARGO Therapeutics based?+
CARGO Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026